St. Jude launches neurostim device that can handle software updates; FDA to set conflict-of-interest rules for advisory panel members;

@FierceMedDev: J&J gets a mixed verdict in a trial alleging it sold faulty vaginal mesh implants. More | Follow @FierceMedDev

@MarkHFierce: ICYMI: Biotronik may have a relatively small U.S. mkt share, but it is working hard to compete here. Story | Follow @MarkHFierce

@MichaelGFierce: The year in nanotech drug delivery. Special report | Follow @MichaelGFierce

@EmilyWFierce: Adhesive medical sensors with origami-like wires could flex and bend with the skin, say researchers at Northwestern University. News | Follow @EmilyWFierce

> St. Jude Medical ($STJ) won FDA approval for a neurostimulation system to treat chronic pain that allows spinal cord stimulation technology upgrades, as they are approved, to be made via software updates. Release

> Roche's ($RHHBY) Ventana medical systems will work with a Danish drug company, in part, to develop an immunohistochemistry companion diagnostic test that detects tissue factor in patient tumor samples. Release

> Escalon Medical ($ESMC) in Pennsylvania gained the FDA's 510(k) clearance for a new tablet-based ultrasound imaging system. Release

> Evonik will open research sites in the U.S and Germany focused on developing biomaterials and polymers for implantable medical technology. Story

> The FDA has decided that experts who serve on agency advisory panels that evaluate new medical devices and drugs must disclose conflicts of interest. Story

Biotech News

@FierceBiotech: For those of you just waking up and getting to work in the U.S., here's our second issue of EuroBiotech: Read | Follow @FierceBiotech

@JohnCFierce: Amgen down 1.7%. I'm going to start calling Amgen a pharma co. If it walks like a duck... | Follow @JohnCFierce

@DamianFierce: Amgen: T-Vec hits on durable response but misses on OS, its secondary endpoint. Release | Follow @DamianFierce

@EmilyMFierce: The current environment for cancer care in Europe: Infographic via Janssen | Follow @EmilyMFierce

> AbbVie gets out of the way as the EU prepares for trial transparency. More

> Merck and Ferring team up on anti-bleeding drug for the developing world. News

> GTx's CEO finds the door as the company moves on from a PhIII failure. Article

Pharma News

@FiercePharma: Trending on FierceVaccines: GSK will tailor vaccine portfolio, improve access as part of wider Africa initiative. More | Follow @FiercePharma

@TracyStaton: Still best-read FiercePharma: It's a big win for Eli Lilly in multibillion-dollar Alimta patent fight. Story | Follow @TracyStaton

@EricPFierce: RT: Last year, my sister died, and I learned first-hand about life sciences' limits. Article from FierceMedicalDevices | Follow @EricPFierce

@CarlyHFierce: Amgen, GSK part on fast-selling Prolia, mostly. More | Follow @CarlyHFierce

> Meda spurns Mylan takeover bid. News

> FDA's OK of opioid overdose treatment doesn't quell backlash over Zohydro. Article